Cost-effectiveness model of Palivizumab in The Netherlands

被引：0
|
作者：
Nuijten, MJ
Lebmeier, M
Daalderop, P
Wittenberg, W
机构：
[1] Erasmus Univ, Jisp, AL, Netherlands
[2] Univ Sheffield, Sheffield, S Yorkshire, England
[3] Abbott BV, Hoofddorp, Netherlands
[4] Dept Hlth Econ & Outcomes Res, Ludwigshafen, Germany
来源：
VALUE IN HEALTH | 2005年 / 8卷 / 06期
关键词：
D O I：
10.1016/S1098-3015(10)67298-1
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A52 / A52
页数：1
相关论文
共 50 条
  • [1] Cost-effectiveness model of palivizumab in the UK
    Nuijten, MJ
    Lebmeier, M
    Wittenberg, W
    VALUE IN HEALTH, 2005, 8 (06) : A62 - A62
  • [2] The cost-effectiveness of Palivizumab in Austria
    Resch, B
    Nuijten, MJ
    Lebmeier, M
    Wittenberg, W
    Gusenleitner, W
    VALUE IN HEALTH, 2006, 9 (03) : A94 - A94
  • [3] Cost-effectiveness of palivizumab in New Zealand
    Vogel, AM
    McKinlay, MJ
    Ashton, T
    Lennon, DR
    Harding, JE
    Pinnock, R
    Graham, D
    Grimwood, K
    Pattemore, PK
    Schousboe, M
    JOURNAL OF PAEDIATRICS AND CHILD HEALTH, 2002, 38 (04) : 352 - 357
  • [4] Cost-effectiveness model for a specific mixture of prebiotics in The Netherlands
    I. Lenoir-Wijnkoop
    W. M. C. van Aalderen
    G. Boehm
    D. Klaassen
    A. B. Sprikkelman
    M. J. C. Nuijten
    The European Journal of Health Economics, 2012, 13 : 101 - 110
  • [5] Cost-effectiveness model for a specific mixture of prebiotics in The Netherlands
    Lenoir-Wijnkoop, I.
    van Aalderen, W. M. C.
    Boehm, G.
    Klaassen, D.
    Sprikkelman, A. B.
    Nuijten, M. J. C.
    EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2012, 13 (01): : 101 - 110
  • [6] The cost-effectiveness of zemplar in the Netherlands
    Nuijten, MJ
    Siegert, C
    VALUE IN HEALTH, 2006, 9 (03) : A7 - A8
  • [7] A review of cost-effectiveness of palivizumab for respiratory syncytial virus
    Hussman, Julia M.
    Li, Abby
    Paes, Bosco
    Lanctot, Krista L.
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2012, 12 (05) : 553 - 567
  • [8] Cost-effectiveness of respiratory syncytial virus prophylaxis with palivizumab
    Reeve, Carole A.
    Whitehall, John S.
    Buettner, Petra G.
    Norton, Robert
    Reeve, David M.
    Francis, Fleur
    JOURNAL OF PAEDIATRICS AND CHILD HEALTH, 2006, 42 (05) : 253 - 258
  • [9] Cost-effectiveness of respiratory syncytial virus prophylaxis with palivizumab
    Mahadevia, Parthiv J.
    Malinoski, Frank J.
    ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE, 2007, 161 (05): : 519 - 520
  • [10] Cost-effectiveness of rotavirus vaccination in the Netherlands; the results of a consensus model
    Mark H Rozenbaum
    Marie-Josee J Mangen
    Carlo Giaquinto
    Jan C Wilschut
    Eelko Hak
    Maarten J Postma
    BMC Public Health, 11
12345